EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY 4.0

A Phase 1B Trial in GBA1 ‐ Associated Parkinson's Disease of BIA‐28‐6156, a Glucocerebrosidase Activator

Jonas M den Heijer iD, Annelieke C Kruithof, Matthijs Moerland, Mike Walker, Lindsay Dudgeon, Craig Justman, Imelda Solomini, Leslie Splitalny, Nancy Leymarie, Kshitij Khatri iD, Valerie C Cullen, Dana C Hilt und 2 weitere

Movement Disorders · 2023-07 · 38 (7) · 1197-1208

DOI: 10.1002/mds.29346 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders, online erschienen am 17.05.2023. Verfasst von Jonas M den Heijer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Centre for Human Drug Research, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Loss‐of‐function mutations in the GBA1 gene are one of the most common genetic risk factors for onset of Parkinson's disease and subsequent progression (GBA‐PD). GBA1 encodes the lysosomal enzyme glucocerebrosidase (GCase), a promising target for a possible first disease‐modifying therapy. LTI‐291 is an allosteric activator of GCase, which increases the activity of normal and mutant forms of GCase.

Objectives

This first‐in‐patient study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of 28 daily doses of LTI‐291 in GBA‐PD.

Methods

This was a randomized, double‐blind, placebo‐controlled trial in 40 GBA‐PD participants. Twenty‐eight consecutive daily doses of 10, 30, or 60 mg of LTI‐291 or placebo were administered (n = 10 per treatment allocation). Glycosphingolipid (glucosylceramide and lactosylceramide) levels were measured in peripheral blood mononuclear cells (PBMCs), plasma, and cerebrospinal fluid (CSF), and a test battery of neurocognitive tasks, the Movement Disorder Society‐Unified Parkinson's Disease Rating Scale and the Mini‐Mental State Exam, were performed.

Results

LTI‐291 was generally well tolerated, no deaths or treatment‐related serious adverse events occurred, and no participants withdrew due to adverse events. C max , and AUC 0–6 of LTI‐291 increased in a dose‐proportional manner, with free CSF concentrations equal to the free fraction in plasma. A treatment‐related transient increase in intracellular glucosylceramide (GluCer) in PBMCs was measured.

Conclusion

These first‐in‐patient studies demonstrated that LTI‐291 was well tolerated when administered orally for 28 consecutive days to patients with GBA‐PD. Plasma and CSF concentrations that are considered pharmacologically active were reached (ie, sufficient to at least double GCase activity). Intracellular GluCer elevations were detected. Clinical benefit will be assessed in a larger long‐term trial in GBA‐PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseHumansGlucosylceramidaseLeukocytes, MononuclearGlucosylceramidesDouble-Blind MethodMutation

Stichwörter der Autor:innen

clinical trialdisease modificationgeneticglucosylceramidase betaparkinsonism

Substanzen

GlucosylceramidaseGlucosylceramides

Autor:innen und Institutionen

  • Department of Neurology, Centre for Human Drug Research, Leiden, the Netherlands.
  • Leiden University Medical Centre, Leiden, the Netherlands.
  • Certara, QSP, Canterbury, United Kingdom.
  • Lysosomal Therapeutics Inc., Cambridge, Massachusetts, USA.
  • Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Jonas M den Heijer, Kshitij Khatri

Zitieren

APA

den Heijer, J. M., Kruithof, A. C., Moerland, M., Walker, M., Dudgeon, L., Justman, C., Solomini, I., Splitalny, L., Leymarie, N., Khatri, K., Cullen, V. C., Hilt, D. C., Groeneveld, G. J., & Lansbury, P. (2023). A Phase 1B Trial in GBA1 ‐ Associated Parkinson's Disease of BIA‐28‐6156, a Glucocerebrosidase Activator. Movement Disorders, 38(7), 1197-1208. https://doi.org/10.1002/mds.29346

Vancouver

den Heijer JM, Kruithof AC, Moerland M, Walker M, Dudgeon L, Justman C, et al. A Phase 1B Trial in GBA1 ‐ Associated Parkinson's Disease of BIA‐28‐6156, a Glucocerebrosidase Activator. Movement Disorders. 2023;38(7):1197-1208. doi:10.1002/mds.29346

BibTeX
@article{denHeijer2023,
  author = {den Heijer, Jonas M and Kruithof, Annelieke C and Moerland, Matthijs and Walker, Mike and Dudgeon, Lindsay and Justman, Craig and Solomini, Imelda and Splitalny, Leslie and Leymarie, Nancy and Khatri, Kshitij and Cullen, Valerie C and Hilt, Dana C and Groeneveld, Geert Jan and Lansbury, Peter},
  title = {A Phase 1B Trial in GBA1 ‐ Associated Parkinson's Disease of BIA‐28‐6156, a Glucocerebrosidase Activator},
  journal = {Movement Disorders},
  year = {2023},
  volume = {38},
  number = {7},
  pages = {1197--1208},
  doi = {10.1002/mds.29346}
}
Kostenlos starten →